CoChat

Targeting the hepcidin–ferroportin pathway in anaemia of chronic kidney disease

Open access
Sheetz, Matthew, Barrington, Philip, Callies, Sophie, Berg, Paul H., McColm, Juliet, Marbury, Thomas, Decker, Brian, Dyas, Gregory L., Truhlar, Stephanie M.E., Benschop, Robert, Leung, Donmienne, Berg, Jolene, Witcher, Derrick R. · 2019 · British Journal of Clinical Pharmacology
Cited by 76

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Aims: Erythropoiesis‐stimulating agents used to treat anaemia in patients with chronic kidney disease (CKD) have been associated with cardiovascular adverse events. Hepcidin production, controlled by bone morphogenic protein 6 (BMP6), regulates iron homeostasis via interactions with the iron transporter, ferroportin. High hepcidin levels are thought to contribute to increased iron sequestration and subsequent anaemia in CKD patients. To investigate alternative therapies to erythropoiesis‐stimulating agents for CKD patients, monoclonal antibodies, LY3113593 and LY2928057, targeting BMP6 and ferroportin respectively, were tested in CKD patients. Methods: Preclinical in vitro/vivo data and clinical data in healthy subjects and CKD patients were used to illustrate the translation of pharmacological properties of LY3113593 and LY2928057, highlighting the novelty of targeting these nodes within the hepcidin–ferroportin pathway. Results: LY2928057 bound ferroportin and blocked interactions with hepcidin, allowing iron efflux, leading to increased serum iron and transferrin saturation levels and increased hepcidin in monkeys and humans. In CKD patients, LY2928057 led to slower haemoglobin decline and reduction in ferritin (compared to placebo). Serum iron increase was (mean [90% confidence interval]) 1.98 [1.46–2.68] and 1.36 [1.22–1.51] fold‐relative to baseline following LY2928057 600 mg and LY311593 150 mg respectively in CKD patients. LY3113593 specifically blocked BMP6 binding to its receptor and produced increases in iron and transferrin saturation and decreases in hepcidin preclinically and clinically. In CKD patients, LY3113593 produced an increase in haemoglobin and reduction in ferritin (compared to placebo). Conclusion: LY3113593 and LY2928057 pharmacological effects (serum iron and ferritin) were translated from preclinical‐to‐clinical development. Such interventions may lead to new CKD anaemia treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bcp.13877

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 30

  1. 10.7326/0003-4819-153-1-201007060-00252 · DOI · Paper page
  2. 10.1056/NEJMoa062276 · DOI · Paper page
  3. 10.2215/CJN.02380607 · DOI
  4. 10.1080/14656566.2017.1323872 · DOI
  5. 10.1681/ASN.2014090922 · DOI
  6. 10.1097/00002480-199407000-00122 · DOI
  7. 10.1371/journal.pone.0123072 · DOI
  8. 10.3324/haematol.2009.014399 · DOI · Paper page
  9. 10.1126/science.1104742 · DOI · Paper page
  10. 10.1002/ajh.23110 · DOI · Paper page
  11. 10.1016/j.bbagen.2008.08.006 · DOI · Paper page
  12. 10.3324/haematol.2011.048926 · DOI · Paper page
  13. 10.1182/blood-2011-03-339952 · DOI · Paper page
  14. 10.1111/bph.13883 · DOI · Paper page
  15. 10.1182/blood-2006-11-057471 · DOI · Paper page
  16. 10.1093/nar/gkx1121 · DOI · Paper page
  17. 10.1111/bph.13877 · DOI · Paper page
  18. 10.1016/S0301-472X(01)00723-8 · DOI
  19. 10.1186/s13045-017-0427-x · DOI · Paper page
  20. 10.1208/s12248-010-9222-0 · DOI
  21. 10.1002/(SICI)1520-6408(1998)22:4<321::AID-DVG3>3.0.CO;2-8 · DOI · Paper page
  22. 10.1371/journal.pcbi.1003421 · DOI
  23. 10.1038/ki.2009.503 · DOI · Paper page
  24. 10.1016/j.bcmd.2005.04.005 · DOI
  25. 10.1053/j.ajkd.2015.12.020 · DOI · Paper page
  26. 10.1053/ajkd.2001.22433 · DOI · Paper page
  27. 10.1007/s10157-010-0288-x · doi:10.1007/s10157-010-0288-x
  28. 10.1038/ki.2014.114 · DOI · Paper page
  29. 10.1681/ASN.2015010052 · DOI
  30. 10.1093/ndt/gfs488 · DOI

Cited by

See all 76

Metadata

Authors
Sheetz, M., Barrington, P., Callies, S., Berg, P. H., McColm, J., Marbury, T., Decker, B., Dyas, G. L., Truhlar, S. M. E., Benschop, R., Leung, D., Berg, J., & Witcher, D. R.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2019-03-04
Volume
85
Issue
5
Pages
935-948
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2913829274
Cited by
76
References
21
FWCI
7.40
Type
journal article
Language
en
Open access
bronze
Funders
Eli Lilly and Company

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.